Taylor Wessing acts for f-star on therapeutic technology collaboration

Taylor Wessing has acted for antibody engineering company f-star on a collaboration and license agreement with Boehringer Ingelheim for joint discovery of new antibody-derived therapeutic products based on f-star’s Modular Antibody Technology.

f-star is based in Vienna, Austria and Cambridge, UK. The company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional antigen-binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Since its founding in 2006 the company has raised EUR 19.0m from Atlas Venture, Aescap Venture, Novo Ventures, TVM Capital, Merck Serono Ventures and MP Helathcare Venture Management.

Dr Kevin FitzGerald, CEO of f-star, commented:“We are very pleased to have completed this agreement with Boehringer Ingelheim and are very excited by the prospect of jointly delivering novel therapeutic proteins to patients with poorly treated illnesses. F-star has developed novel technology for the discovery of antibody-based products that are clearly differentiated from conventional antibodies and other protein-based drugs. This partnership will enable f-star to expand the exploitation of this technology by combining with the impressive global research and development capabilities and resources of Boehringer Ingelheim”.

ENDS

Lawyers Malcolm Bates

Notes to Editors

For more information please contact Sarah Le Cheminant at Taylor Wessing:

Sarah Le Cheminant
DDL + 44 (0) 20 7300 4930
Email